Method to ameliorate inflammation
Administering to a patient a concentration of at least one anti-inflammatory agent and bevacizumab at a concentration sufficient to reduce fluid leakage from new vessels associated with angiogenesis.
1 . A method for ameliorating an ocular inflammatory process in a patient comprising providing to the patient a therapeutic concentration of at least one anti-inflammatory agent and bevacizumab at a concentration sufficient to reduce ocular angiogenesis and inflammation and their sequelae.
2 . The method of claim 1 further comprising providing another anti-VEGF compound, an anti-PDGF compound, an anti-leukotriene, or combinations thereof.
3 . The method of claim 1 wherein bevacizumab is at a concentration up to about 5 mg/0.1 ml.
4 . The method of claim 1 where bevacizumab is administered topically to an eye at a concentration up to about 5 mg/ml.
5 . (canceled)
6 . The method of claim 1 where bevacizumab is administered intraocularly at a concentration ranging from about 0.05 mg/ml to about 5 mg/ml.
7 . The method of claim 1 wherein the anti-inflammatory agent is selected from at least one of colchicine, a steroid, a matrix metalloproteinase inhibitor, or a macrolide.
8 . (canceled)
9 . A method for ameliorating an ocular inflammatory process in a patient comprising providing to the patient a therapeutic concentration of at least one anti-inflammatory agent and bevacizumab at a concentration sufficient to reduce ocular angiogenesis.
10 . The method of claim 9 wherein bevacizumab is administered topically, systemically, or by intraocular injection.
11 - 14 . (canceled)